Inclusion Criteria

• Patient must have a histologically confirmed diagnosis of Kaposi's sarcoma.
• Positive antibody to HIV confirmed by ELISA or Western blot on the same serum.

Exclusion Criteria

• Active drug or alcohol abuse.

Co-existing Condition:

Patients with the following complications are excluded:

• Active opportunistic infections requiring ongoing therapy.
• Pneumocystis carinii pneumonia (PCP) unless recovered must be off therapy within 90 days prior to study.
• Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia.
• Concurrent neoplasms other than basal cell carcinoma of skin.
• Known sensitivity to polymycin or neomycin.

Patients with the following complications are excluded:

• Active opportunistic infections requiring ongoing therapy.
• Pneumocystis carinii pneumonia (PCP) unless recovered must be off therapy within 90 days prior to study.
• Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia.
• Concurrent neoplasms other than basal cell carcinoma of skin.
• Known sensitivity to polymycin or neomycin.

Prior Medication:

Excluded:

• Any prior zidovudine (AZT) or interferon alpha protocol participation.
• Excluded within 30 days of study entry:
• Immunomodulating agents.
• Other drugs that can cause neutropenia or significant nephrotoxicity, or systemic anti-infectives.
• Excluded within 90 days of study entry:
• Antiretroviral agents.
• Treatment of Pneumocystis carinii pneumonia (PCP).

Prior Treatment:

Excluded within 30 days of study entry:

• Radiation therapy.